Loading
A phase 3 trial of Abiraterone acetate, Niraparib and Prednisone in prostate cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC) is a phase 3 interventional study registered as NCT04497844 by Janssen Research & Development, LLC, with 696 participants enrolled, started 2020-09-23 and due to reach its primary completion in 2025-01-07. Interventions recorded: Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone, Placebo FDC and Placebo AA. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
696 enrolled.
95% CI 22.11 to 41.17; Figures from the ClinicalTrials.gov results section (first posted 2026-01-22), not from a publication · Median and the upper limit of the 95% confidence interval (CI) were not estimable due to an insufficient number of participants with events.
Source95% CI 25.59 to NA; Figures from the ClinicalTrials.gov results section (first posted 2026-01-22), not from a publication · Median and the upper limit of the 95% CI were not estimable due to an insufficient number of participants with events.
Source95% CI 25.82 to NA; Figures from the ClinicalTrials.gov results section (first posted 2026-01-22), not from a publication · Median and the upper limit of the 95% CI were not estimable due to an insufficient number of participants with events.
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigatorprimary | BRCA Subgroup: Placebo With Abiraterone Acetate Plus Prednisone | 196 | 25.99 months | 0.515 (0.37 to 0.717) | <0.0001 | link |
| BRCA Subgroup: Niraparib With Abiraterone Acetate Plus Prednisone | 191 | Median and the upper limit of the 95% confidence interval (CI) were not estimable due to an insufficient number of participants with events. | ||||
| HRR Effector Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigatorprimary | HRR Effector Subgroup: Placebo With Abiraterone Acetate Plus Prednisone | 226 | 27.56 months | 0.571 (0.421 to 0.774) | 0.0003 | link |
| HRR Effector Subgroup: Niraparib With Abiraterone Acetate Plus Prednisone | 230 | Median and the upper limit of the 95% CI were not estimable due to an insufficient number of participants with events. | ||||
| All HRR: Radiographic Progression-free Survival (rPFS) Assessed by Investigatorprimary | Placebo With Abiraterone Acetate Plus Prednisone | 348 | 29.54 months | 0.625 (0.49 to 0.799) | 0.0001 | link |
| Niraparib With Abiraterone Acetate Plus Prednisone | 348 | Median and the upper limit of the 95% CI were not estimable due to an insufficient number of participants with events. |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Niraparib, Abiraterone acetate, Prednisone, Johnson & Johnson and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prednisone, Johnson & Johnson and the tag pipeline.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag pipeline.
Shares Metastatic hormone-sensitive prostate cancer, Androgen deprivation & AR pathway inhibitors, PARP inhibitors, Prostate cancer and the tag pipeline.
Shares Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Prostate cancer and the tag pipeline.
Shares Metastatic hormone-sensitive prostate cancer, Prednisone, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/